Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

We evaluated the efficacy of carboplatin, irinotecan, and bevacizumab among bevacizumab-naïve, recurrent glioblastoma (GBM) patients in a phase 2, open-label, single arm trial. Forty eligible patients received carboplatin (area under the plasma curve [AUC] 4 mg/ml-min) on day one, while bevacizumab...

Full description

Saved in:
Bibliographic Details
Main Authors: Reardon, David A., Desjardins, Annick, Peters, Katherine B., Gururangan, Sridharan, Sampson, John H., McLendon, Roger E., Herndon, James E., Bulusu, Anuradha, Threatt, Stevie, Friedman, Allan H., Vredenburgh, James J., Friedman, Henry S.
Format: Artigo
Language:Inglês
Published: 2011
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3616617/
https://ncbi.nlm.nih.gov/pubmed/21986722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-011-0722-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items